Solara Active Pharma Sciences LtdQ4 FY26
Solara Active Pharma Sciences Ltd Q4 FY26 Earnings Call Analysis
Revenue, margin, capex, fundraise and order book outlook from management commentary.
Price: ₹570Market Cap: ₹2.1K CrSector: Pharmaceuticals & Biotechnology
Management growth scorecard
Revenue
Category 3
Margin
Category 3
Fundraise
N/A
Order
N/A
Capex
Yes
1 of 3 growth signals are positive — mixed outlook.
Full analysisRevenue guidance
Category 3No information is provided regarding the same in the latest conference call.
Margin guidance
Category 3No information is provided regarding the same in the latest conference call.
3 more insights locked — sign up free to unlock
Fundraise plans
No information is provided regarding the same in the latest conference call.
Order book
- →The transcript does not explicitly mention the current or expected order book or pending orders for Solara Active Pharma Sciences Limited.
- →The company highlighted six key product approvals and 11 market extensions in Q3, focusing on portfolio maximization, new geographies, and new customers, which implies future order inflows.
- →The CRAMS business order pipeline seems positive with plans to grow revenue to approximately Rs. 500 crores in 3-4 years.
- →The Vizag CRAMS facility retrofit and investments suggest ongoing and future projects.
- →The company is focusing on cost improvements and margin expansion, implying they expect steady demand.
- →Overall, no quantitative order book details provided, but ongoing approvals and investments indicate a growing order pipeline.
Capex plans
YesNo information is provided regarding the same in the latest conference call.
How does Solara Active Pharma Sciences Ltd rank vs peers in Pharmaceuticals & Biotechnology?
Pro feature1Solara Active Pharma Sciences Ltd
Rev 3Mar 3
See full Pharmaceuticals & Biotechnology sector rankings
Want more stocks like Solara Active Pharma Sciences Ltd?
Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.
Build my portfolio